Sentinel Lymph Node Mapping of Breast Cancer via Intradermal Administration of Lymphoseek

摘要

Lymphoseek™ is a molecular imaging agent specifically designed for sentinel lymph node (SLN) mapping. We conducted a Phase I trial which measured the injection site clearance and sentinel lymph node accumulation after a single intra-dermal injection of Lymphoseek or [^99mTc]sulfur colloid protocol. Ten patients with breast cancer participated in this study. Five patients received an intradermal administration of 1.0 nmole of ^99mTc-labeled Lymphoseek and five patients received an intra-dermal administration of filtered [^99mTc]sulfur colloid (fTcSC). Lymphoseek, exhibited a significantly (P < .001) faster injection site clearance than fTcSC. The mean Lymphoseek clearance half-time was 2.61 ± 0.72 hr compared to 24.1 ± 17.7 hr for fTcSC. The mean sentinel lymph node uptake of Lymphoseek (1.1 ± .5%), and TcSC (2.5 ± 4.9%) were statistically equivalent (P = 0.28). When an intra-dermal injection was employed, Lymphoseek demonstrated faster injection site clearance than filtered [^99mTc]sulfur colloid.